Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05578027
Other study ID # 677/HDDD-DHYD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date June 30, 2023

Study information

Verified date October 2023
Source University of Medicine and Pharmacy at Ho Chi Minh City
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Moxibustion plays an important role in Traditional Medicine treatments, which treats and prevents diseases by burning a herb preparation containing Moxa (Artemisia vulgaris, Mugwort) to stimulate the meridians of human body. Moxibustion is considered a safe and effective traditional therapy. Mild moxibustion is a kind of therapeutic method which characterized by wide indications, simple manipulation and comfortable feeling, is commonly used in clinical treatment. Mingmen acupoint located on the midline of the lower back, in the depression below the spinous process of the 2nd lumbar vertebra (L2). Its indications include Yang-deficiency syndrome, Cold-Stagnation syndrome, Cold Excessive syndrome,... and it is closely related to the knee area through the path of Thoroughfare Vessel (one of the Eight Extraordinary Vessels). In our study, we investigate the change in skin surface temperature at the knee area on both sides when using mild moxibustion manipulation at Mingmen acupoint with moxa stick in healthy volunteers.


Description:

Participants and Methods: A randomized controlled trial is conducted by comparing the change in skin surface temperature before and after using mild moxibustion manipulation at the research acupoint (Mingmen (GV-4) acupoint) or the control acupoint (the left side Pishu (BL-20) acupoint) in healthy volunteers. A total of 38 participants will undergo 2 trial phases, corresponding to 2 times of moxibustion in 8 days, each time is 7 days apart. In the first trial phase: participants received moxibustion at left side Pishu (BL-20) acupoint. In the second trial phase: participants received moxibustion at Mingmen (GV-4) acupoint. The primary outcome was the change in skin surface temperature at the local stimulated area and the knee area on both sides when using mild moxibustion manipulation at Mingmen acupoint. This trial will be performed as a pilot study.


Recruitment information / eligibility

Status Completed
Enrollment 38
Est. completion date June 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - Healthy males and females were individual age between enough 18 and 30 years old. - BMI: 18.5 - 23 kg/m2 - Mental alertness, good contact, cooperation with researchers. - Had no psychiatric stress problem during moxibustion day (confirmed by answering the DASS 21 questionaire with stress point less than 15 points). - Had no history of cardio-vascular disease, diabetes, hyperthyroidism, hypothyroidism. - Vital sign within normal limits: - Heart rates from from 60 to 99 beats/minute. - Systolic blood pressure between 90 and 139 mmHg. - Diastolic blood pressure between 60 and 89 mmHg. - Breathing rate: 16 ± 3 times/minute. - Body temperature: 36.59 ± 0.43 ?. - SpO2 from 95 to 100%. - Volunteers who agree to participate and sign the Informed Consent Form, following a detailed explanation of clinical trials. - Not currently participating in other intervention studies. Exclusion Criteria: - Having an inflammatory injury in the site of the skin to be investigated. - Medical history of asthma or allergy with moxa smoke. - Using heat therapy, for example massage, cupping therapy, acupuncture in the site of the skin to be investigated within 24 hours. - Applying chemical or pharmaceutical products to the site of the skin to be survey before conducting the study. - Other diseases that could affect or interfere with outcomes, including common cold or flu. - Playing sport 2 hours before the study. - Taking stimulants such as beer, alcohol, coffee and tobacco within 24 hours before conducting the study. - Skin surface temperature disorders or sensation disorders at lower-back or knee area. - Staying up at night or having insomnia before moxibustion day. - Women during menstruation period, pregnancy, or breastfeeding. - Currently using certain drugs which dilate blood vessels and drop in blood pressure.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Mild moxibustion with moxa stick
To conduct this intervention, we used moxa sticks which were 1.5 cm in diameter, 13 cm long, and weighed 12 gram to perform mild moxibustion manipulation at the control acupoint (the left side Pishu acupoint) or Mingmen acupoint in 2 trial phases. The main ingredient of the moxa was dried mugwort leaf, produced in Vietnam. All moxa materials were obtained from the Sai Gon TCS Co., Ho Chi Minh City, Vietnam.

Locations

Country Name City State
Vietnam Faculty of Traditional medicine - University of Medicine and Pharmacy of Ho Chi Minh City Ho Chi Minh City

Sponsors (1)

Lead Sponsor Collaborator
Bui Pham Minh Man

Country where clinical trial is conducted

Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in skin surface temperature at the local stimulated area when using mild moxibustion manipulation at Mingmen acupoint During procedure
Primary Change in skin surface temperature at the knee area on both sides when using mild moxibustion manipulation at Mingmen acupoint During procedure
See also
  Status Clinical Trial Phase
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1